Incyte grabs a new PD-1 checkpoint drug in $900M deal with MacroGenics
Incyte $INCY has just inked a $900 million deal to grab global rights to an early-stage PD-1 checkpoint now being developed at MacroGenics.
The two companies announced Wednesday morning that Incyte will pay $150 million in a cash upfront for the development and commercialization rights to MGA012, with MacroGenics hanging on to rights for running combination studies using their pipeline cancer drug assets.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.